Copyright
©The Author(s) 2023.
World J Clin Cases. Sep 16, 2023; 11(26): 6105-6121
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6105
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6105
Antibody | Mechanism | Company | Stage of study/identification method |
Canakinumab | IL-1β inhibitor | Novartis | In clinical stage for several inflammatory diseases including arthritis, periodic fever and lung cancer; repurposed by novartis for COVID-19 |
Secukinumab (cosentyx®) | IL-17 inhibitor | Novartis | In clinical stage for several autoimmune diseases including psoriasis; repurpose by novartis for COVID-19 |
TZLS-501 | Fully human monoclonal antibody targeting the receptor of IL-6, it binds to both membrane-bound and soluble forms of IL-6R, and rapidly depletes the circulating levels of IL-6 in blood | Tiziana Life Sciences and Novimmune | Preclinical stage |
Pritumumab | Fully human IgG antibody targeting vimentin | Nascent Biotech Inc. | Received FDA approve for several carcinoma; Research began for COVID-19 |
COVID-HIG and COVID-EIG | Hyperimmune polyclonal antibody derived from human plasma or immunized horse | Emergent BioSolutions | Enter clinical trial within 4-5mo |
Rcig | Recombinant anti SARS-CoV-2 hyperimmune gamma globulin, polyclonal antibodies | GigaGen | Preclinical stage-Aimed for COVID19 hospitalized patients and prophylaxis in high-risk individuals |
Antibody cocktail including REGN3048-3051 | Fully human multivalent antibodies against the spike protein isolated from genetically modified mice or recovered COVID-19 patients | Regeneron | Phase 1 clinical trial for Middle East Respiratory Syndrome completed last year; clinical trial for SARS-CoV-2 starts by early summer |
- Citation: Hegazy SK, Tharwat S, Hassan AH. Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients. World J Clin Cases 2023; 11(26): 6105-6121
- URL: https://www.wjgnet.com/2307-8960/full/v11/i26/6105.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i26.6105